5Yuan HY,Chen JJ,Lee MT,et al.A novel functional VKORC 1 promoter polymorphism is associated with in the individual and intercthnic difference in warfarin sensitivity[J].Hum Molgene,2005,4(3)1745-1751.
6Kajinami K,Takekoshi N,Brousseau ME,et al.Pharmacogenetics of HMG-CoA reductas inhibitors:exploring the potential for genotype-based individualization of coronary heart disease management[J].Atherosclerosis,2004,177(2)219-234.
7Niemi M,Cascorbi I,Timm R,et al.Glyburide and glimepiride pharmacoRinetics in subjects wita different cypzc9 genotypes[J].Clin Pharmacol Ther,2002,72(3)326-332.
8Yin OQ,Tomlinson B,Chow MS.Cypzc9,but not cypzc19,polymorphisms affect the pharmaco rineties and pharmacodynamics of glyburide in chinese subjects[J].Clin Pharmacol Ther,2005,78(4)370-377.
7[3]Marceau F, Hess JF, Bachvarov DR, et al. The B1 receptors for kinins. Pharmacol Rev,1998,50(3) :357-386.
8[4]Fredrik LM, Leeb-Lundberg, Marceau F, et al. International Union of Pharmacology. XLV. Classification of the kinin receptor family:from molecular mechanisms to pathophysiological consequences.Pharmacol Rev,2005,57: 27 -77.
9[5]Schanstra JP, Bataillé E, Barascud Y, et al. The B1-agonist [ desArgl0 ]-kallidin activates transcription factor NF-κB and induces homologous upregulation of the Bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest, 1998,101: 2080-2091.
10[7]Bautista LE , Lopeze JP, Veral LM. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens, 2001,19 (5) :857-2861.
